Abivax S.A.

Upheaval remains the norm in the US biopharmaceutical industry under President Donald Trump, with lingering threats of Food and Drug Administration staffing and policy changes, tariffs and most favore

The years of effort and expense Abivax has put into advancing obefazimod for ulcerative colitis (UC) have paid off now that the French firm has presented stellar results from a pair of Phase III trial

Abivax has spent heavily on advancing obefazimod through late-stage trials for ulcerative colitis (UC) and is eagerly awaiting a readout to see whether its faith in the compound will translate into a

With a star pipeline candidate entering Phase III clinical trials for the treatment for ulcerative colitis, Abivax S.A. is in the midst of a corporate rework to be able to secure funding and ultimat